Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, announced that The Lancet Oncology has published results
View HTML
Toggle Summary Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results
- Completed full enrollment of luspatercept MEDALIST and BELIEVE Phase 3 trials - - Presented updated luspatercept Phase 2 results in patients with MDS and beta-thalassemia receiving treatment for up to two years - - Treated first patient in ACE-083 Phase 2 study in Charcot-Marie-Tooth disease - -
View HTML
Toggle Summary Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease
- Phase 2 trial in CMT expands wholly-owned ACE-083 program and muscle franchise into new area of high unmet medical need - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and
View HTML
Toggle Summary Acceleron to Webcast Second Quarter 2017 Financial Results on August 3, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 3, 2017 at 5:00 p.m. EDT to discuss its second quarter 2017 financial results and provide an update on recent clinical development and corporate
View HTML
Toggle Summary Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association
- Results from ongoing trials demonstrate increases in hemoglobin and reductions in red blood cell transfusion burden sustained for more than 26 months - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery,
View HTML
Toggle Summary Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association
Results from ongoing study demonstrate increases in hemoglobin and decreases in red blood cell transfusion burden sustained for up to 24 months, with patients still active on treatment CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical
View HTML
Toggle Summary Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma
- DART Phase 2 study of dalantercept plus axitinib did not achieve its primary endpoint - - Acceleron to discontinue development of dalantercept - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery,
View HTML
Toggle Summary Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia
- Companies expect to report top-line results from the Phase 3 studies in mid-2018 - SUMMIT, N.J. & CAMBRIDGE, Ma. --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIST and BELIEVE
View HTML
Toggle Summary Acceleron to Participate in Two Healthcare Investor Conferences in June
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in
View HTML
Toggle Summary Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association
- Presentations to highlight efficacy, duration of response, and long-term safety results from ongoing Phase 2 studies with luspatercept in myelodysplastic syndromes and beta-thalassemia - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical
View HTML